Improving blood tests to better manage lupus disease activity
Commercialization Readiness of Immune Mediator Based Blood Tests that Inform Concurrent and Future Clinical Disease Activity in Systemic Lupus Erythematosus (SLE)
This study is working on new blood tests to help people with lupus better understand their disease and catch flare-ups earlier, so they can get treatment sooner and avoid serious health issues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Progentec Diagnostics, INC. NIH-funded |
| Lab location | 1 site (Oklahoma City, UNITED STATES) |
| Project ID | NIH-11124845 on NIH RePORTER |
What this research studies
This research focuses on developing advanced blood tests that can more accurately predict and monitor disease activity in patients with systemic lupus erythematosus (SLE). By identifying specific immune markers associated with disease flares, the study aims to enable earlier and more proactive treatment, potentially preventing serious organ damage. The approach involves a multi-analyte strategy to assess immune pathways and biomarkers that may signal worsening conditions before traditional symptoms appear. This could lead to improved management of SLE and enhance the quality of life for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus, particularly those experiencing frequent disease flares.
Not a fit: Patients with other autoimmune diseases or those not diagnosed with systemic lupus erythematosus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective monitoring and management of lupus, reducing the risk of organ damage and improving patient outcomes.
How similar studies have performed: Similar research has shown promise in utilizing biomarkers for autoimmune diseases, indicating potential for success in this novel approach.
Where this research is happening
Oklahoma City, UNITED STATES
- Progentec Diagnostics, INC. — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Munroe, Melissa E — Progentec Diagnostics, INC.
- Study coordinator: Munroe, Melissa E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.